| dc.contributor.author | 
Kampa-Schittenhelm, Kerstin Maria | 
 | 
| dc.contributor.author | 
Frey, Julia | 
 | 
| dc.contributor.author | 
Haeusser, Lara A. | 
 | 
| dc.contributor.author | 
Illing, Barbara | 
 | 
| dc.contributor.author | 
Blumenstock, Gunnar | 
 | 
| dc.contributor.author | 
Schittenhelm, Marcus Matthias | 
 | 
| dc.date.accessioned | 
2019-04-23T09:29:12Z | 
 | 
| dc.date.available | 
2019-04-23T09:29:12Z | 
 | 
| dc.date.issued | 
2017 | 
 | 
| dc.identifier.issn | 
1949-2553 | 
 | 
| dc.identifier.uri | 
http://hdl.handle.net/10900/87944 | 
 | 
| dc.language.iso | 
en | 
de_DE | 
| dc.publisher | 
Impact Journals Llc | 
de_DE | 
| dc.relation.uri | 
http://dx.doi.org/10.18632/oncotarget.19970 | 
de_DE | 
| dc.rights | 
info:eu-repo/semantics/closedAccess | 
 | 
| dc.subject.ddc | 
570 | 
de_DE | 
| dc.subject.ddc | 
610 | 
de_DE | 
| dc.title | 
Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia | 
de_DE | 
| dc.type | 
Article | 
de_DE | 
| utue.quellen.id | 
20190131163842_00791 | 
 | 
| utue.publikation.seiten | 
82897-82909 | 
de_DE | 
| utue.personen.roh | 
Kampa-Schittenhelm, Kerstin Maria | 
 | 
| utue.personen.roh | 
Frey, Julia | 
 | 
| utue.personen.roh | 
Haeusser, Lara A. | 
 | 
| utue.personen.roh | 
Illing, Barbara | 
 | 
| utue.personen.roh | 
Pavlovsky, Ashly A. | 
 | 
| utue.personen.roh | 
Blumenstock, Gunnar | 
 | 
| utue.personen.roh | 
Schittenhelm, Marcus Matthias | 
 | 
| dcterms.isPartOf.ZSTitelID | 
Oncotarget | 
de_DE | 
| dcterms.isPartOf.ZS-Issue | 
47 | 
de_DE | 
| dcterms.isPartOf.ZS-Volume | 
8 | 
de_DE | 
| utue.fakultaet | 
04 Medizinische Fakultät | 
de_DE |